<p>Spruce Biosciences Inc. announced new long-term data from clinical analyses of tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB). The results, presented at the 22nd Annual WORLDSymposium™, demonstrated that weekly TA-ERT administration led to rapid and durable normalization of cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE), a surrogate endpoint considered likely to predict clinical benefit. Additionally, the therapy stabilized and preserved cognitive and non-cognitive outcomes, including communication and motor skills, over a six-year period compared to natural history patients. The safety profile was consistent with intracerebroventricular administration, with approximately 6,000 doses administered over six years. Further information and poster presentations are available on the Spruce Biosciences website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260205292673) on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

SPRB

Reuters

Spruce Biosciences

Health Care Select Sector SPDR

VG Health

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Spruce Biosciences Reports Long-Term Efficacy of Tralesinidase Alfa in Sanfilippo Syndrome Type B